Companies Dominating the Allergic Immunotherapy Landscape
- ALK
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Stallergenes Greer
- Mylan N.V.
- HAL Allergy B.V.
- LETIPharma
- AstraZeneca
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of allergy immunotherapy is estimated at USD 1.97 billion.
The global allergy immunotherapy market is anticipated to grow from USD 1.85 billion in 2024 to USD 6.02 billion by 2037, reflecting a CAGR of around 9.5% during the forecast period, from 2025 to 2037.
Asia Pacific industry is set to dominate majority revenue share of 36% by 2037, due to rising presence of major key players in the region.
The major players in the market include ALK, Stallergenes Greer, Mylan N.V., HAL Allergy B.V., LETIPharma, AstraZeneca, Takeda Pharmaceuticals Company Ltd, Chugai Pharmaceutical Co., Ltd, Eisai Co. Ltd, Astellas Pharma Inc.
